bioAffinity Secures Mexican Patent for Lung Cancer Detection Tech
Event summary
- bioAffinity Technologies received notification of a patent allowance in Mexico for its lung cancer detection methods using CyPath® Lung technology.
- The patent covers the use of specific antibodies and porphyrin TCPP to label cell populations in sputum and flow cytometry for lung cancer detection.
- CyPath® Lung combines flow cytometry, AI, and at-home sample collection to assess indeterminate pulmonary nodules in high-risk patients.
- The patent expands bioAffinity's global IP portfolio, which now includes multiple patents in the US, EU, China, Japan, Australia, Canada, and Mexico.
The big picture
The Mexican patent allowance strengthens bioAffinity's intellectual property framework, supporting its mission to provide early-stage lung cancer diagnostics. This move aligns with broader industry trends toward non-invasive, AI-driven diagnostic tools, positioning bioAffinity to capture a growing share of the lung cancer detection market. The company's ability to scale its technology globally will be critical in determining its long-term success.
What we're watching
- IP Expansion
- How the addition of Mexican patent protection will impact bioAffinity's global market strategy and competitive positioning.
- Regulatory Dynamics
- Whether increased FDA oversight of Laboratory Developed Tests could affect the commercialization of CyPath® Lung.
- Commercialization Pace
- The pace at which bioAffinity can leverage its expanded IP portfolio to drive revenue growth in international markets.
Related topics